Un exemple recent en aquest camp \u00e9s la troballa que pacients amb c\u00e0ncer de mama familiar portadores de mutacions en el gen BRCA1 s\u00f3n m\u00e9s sensibles als f\u00e0rmacs anomenats inhibidors de la prote\u00efna PARP (poli-adenosina difosfat ribosa polimerasa). El problema radica en que nom\u00e9s quatre de cada cent pacients de c\u00e0ncer de mama es beneficiarien d’aquest tractament perqu\u00e8 la mutaci\u00f3 de BRCA1 ocorre infreq\u00fcentment.<\/p>\n
La revista oficial de la Societat Americana d’Oncologia M\u00e8dica (ASCO), Journal of Clinical Oncology, ha publicat un estudi coordinat per Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), que est\u00e9n el nombre de pacients susceptibles de rebre aquest tractament.<\/p>\n
El grup del Dr. Esteller ha demostrat que la inactivaci\u00f3 epigen\u00e8tica del gen BRCA1 tamb\u00e9 confereix sensibilitat als inhibidors de PARP en c\u00e8l\u2022lules de c\u00e0ncer de mama. Com un 25% de pacients amb c\u00e0ncer de mama presenten p\u00e8rdues del gen BRCA1 mitjan\u00e7ant aquest mecanisme, s’obre la possibilitat que una de cada quatre dones amb tumors de mama es puguin beneficiar d’aquest nou tractament personalitzat.<\/p>\n
Els autors de l’estudi suggereixen que s’incloguin an\u00e0lisis per detectar la inactivaci\u00f3 epigen\u00e8tica del gen BRCA1 en els assaigs cl\u00ednics que es duen a terme per provar l’efic\u00e0cia dels PARP en pacients amb c\u00e0ncer de mama o d’ovari. <\/p>\n
Refer\u00e8ncia de l’article:<\/strong> La inactivaci\u00f3 epigen\u00e8tica del gen BRCA1 millora l’efecte dels inhibidors de PARP en tumors de mama Refer\u00e8ncia de l’article:<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 22:33:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9724"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9724"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9724\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors. Journal of Clinical Oncology, August 2, 2010.<\/p>\n","protected":false},"excerpt":{"rendered":"